Loading

Concerto Biosciences

June 03, 2024
Company Presentation
Platform for Therapeutics
Company Presentation Theater 4
Concerto Biosciences leverages its unmatched understanding of microbial ecology to discover breakthrough microbe-based therapeutics. The microbiome has been hailed as a promising target for the safe treatment of intractable diseases. However, reliably designing microbe-based therapeutics has remained elusive because no one understands the ecological mechanisms that underpin health-promoting microbiome functions. Concerto unlocks this knowledge with kChip—a platform that physically constructs and evaluates millions of miniature, defined microbial cocultures—and machine learning models of microbial ecology uniquely enabled by massive kChip datasets. Concerto’s lead asset, Ensemble No.2 (ENS-002), is a clinical-stage, topical, multi-strain live biotherapeutic product (LBP) for atopic dermatitis. Our discovery-stage asset, ENS-003, is an intravaginal LBP for recurrent vulvovaginal candidiasis. Through partnerships, we aim to commercialize these assets and launch new discovery initiatives.
Concerto Biosciences
Company Website: http://www.concertobio.com
Lead Product in Development: ENS-002, a topical live biotherapeutic product (LBP) for atopic dermatitis
Number Of Unlicensed Products (For Which You Are Seeking Partners): 3

Company HQ City

Cambridge

Company HQ State

MA

Company HQ Country

United States

CEO/Top Company Official

Cheri Ackerman

Development Phase of Primary Product

Pre-Clinical
Speakers
Cheri Ackerman, PhD
CEO & Cofounder
Concerto Biosciences
Back to Session List

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS